Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

A Kunchok; J Lechner-Scott; F Granella; M Trojano; R Alroughani; P Sola; D Ferraro; A Lugaresi; M Onofrj; S Ozakbas; G Izquierdo; P Grammond; J Luis Sanchez-Menoyo; B Van Wijmeersch; C Boz; E Pucci; P McCombe; F Grand’Maison; D Spitaleri; S Vucic; R Hupperts; V Jokubaitis; MP Sormani; H Butzkueven; T Kalincik

Journal article

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

A Kunchok, J Lechner-Scott, F Granella, M Trojano, R Alroughani, P Sola, D Ferraro, A Lugaresi, M Onofrj, S Ozakbas, G Izquierdo, P Grammond, J Luis Sanchez-Menoyo, B Van Wijmeersch, C Boz, E Pucci, P McCombe, F Grand’Maison, D Spitaleri, S Vucic Show all

Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2021

DOI: 10.1177/1352458520936823

Abstract

Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing–remitting multiple sclerosis (RRMS) treated with interferon-β. Objective: To validate the MAGNIMS score and extend to other disease-modifying therapies (DMTs). To examine the prognostic value of gadolinium contrast-enhancing (Gd+) lesions. Methods: This RRMS MSBase cohort study (n = 2293) used a Cox model to examine the prognostic value of relapses, MRI activity and the MAGNIMS score for disability worsening during treatment with interferon-β and three other DMTs. Results: Three new T2 lesions (hazard ratio..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by Bayer

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was financially supported by the National Health and Medical Research Council of Australia (project grants 1157717 and 1129189 and fellowships 1140766 and 1080518). The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Bayer-Schering, Sanofi Genzyme and Teva. The study was conducted separately and apart from the guidance of the sponsors.